Sana Biotechnology, Inc.
For the period ended Dec 31, 2025. Filed Mar 3, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 3, 2026
SANA$2.43-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Net loss | $(244,166) | $(266,759) | $(283,255) |
| Other comprehensive income: | |||
| Unrealized gain on marketable securities, net | 14 | 74 | 4,267 |
| Total comprehensive loss | $(244,152) | $(266,685) | $(278,988) |
Sana Biotech nology, Inc.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.